Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
GCM Grosvenor Announces Completion of Business Combination
-
CF Finance Acquisition Corp. III Announces Closing of $230 Million Initial Public Offering
-
Trulieve Cannabis Corp (TCNNF) PT Raised to $63 at Cantor Fitzgerald
-
Taseko Announces Closing of US$23 Million Bought Deal Over-Allotment Option Exercised in Full
-
Pre-Open Stock Movers 11/17: (LXRX) (TSLA) (YY) Higher; (BCLI) (GDRX) (CODX) Lower (more...)
-
Companies with NDRs 11/17
-
Acreage Holdings (ACRGF) PT Raised to $4.30 at Cantor Fitzgerald
-
UPDATE: Cantor Fitzgerald Upgrades Tivity Health (TVTY) to Overweight
-
3 Penny Stocks To Buy According To Analysts; 100%-290% Price Targets
-
Denison Announces Establishment of At-The-Market Program
-
Form POS AM Cantor Fitzgerald Income
-
TherapeuticsMD Announces Closing of its Underwritten Public Offering of Common Stock
-
Form 10-Q Cantor Fitzgerald Income For: Sep 30
-
Cassava Sciences (SAVA) Prices $75 Million Public Offering of Common Stock at $8/sh
-
Cassava Sciences Announces Pricing of $75 Million Public Offering of Common Stock
-
Cassava Sciences Announces Pricing of $75 Million Public Offering of Common Stock
-
Companies with NDRs 11/13
-
Orchid Island Capital Announces November 2020 Monthly Dividend and October 31, 2020 RMBS Portfolio Characteristics
-
CF Finance Acquisition Corp. III Announces Pricing of $200 Million Initial Public Offering
-
CF Finance Acquisition Corp. III Announces Pricing of $200 Million Initial Public Offering
-
Cassava Sciences (SAVA) Announces Proposed Public Offering of Common Stock
-
Cassava Sciences Announces Proposed Public Offering of Common Stock
-
Cassava Sciences Announces Proposed Public Offering of Common Stock
-
Retrophin Completes Acquisition of Orphan Technologies
-
Retrophin Completes Acquisition of Orphan Technologies
-
Galmed Pharmaceuticals (GLMD) PT Lowered to $13 at Cantor Fitzgerald
-
Companies with NDRs 11/12
-
Can You Make Money With Penny Stocks? 4 That Analysts Say 'Buy'
-
Taseko Announces US$23 Million Bought Deal and up to US$2 Million Concurrent Private Placement
-
Institute for Portfolio Alternatives Elects New Board Members for 2021
-
Pre-Open Stock Movers 11/11: (FPRX) (FUBO) (SURF) Higher; (EGAN) (ACB) (MODN) Lower (more...)
-
Makor Group Continues Its Growth, Enters Into Strategic Alliance With Churchill Capital
-
Companies with NDRs 11/11
-
After-Hours Movers 11/10: (FPRX) (FUBO) (BRKS) Higher; (EGAN) (MODN) (LYFT) Lower (more...)
-
Vox Royalty Corp (VOX:CN) (VOXCF) PT Raised to Cdn$4 at Cantor Fitzgerald
-
TherapeuticsMD (TXMD) Prices $30 Million Public Offering of Common Stock
-
TherapeuticsMD Announces Pricing of $30 Million Public Offering of Common Stock
-
Companies with NDRs 11/10
-
Penny Stocks Under $1 To Watch This Week; 1 Analyst Sees 200% Upside
-
Canopy Growth (WEED:CN) (CGC) PT Raised to Cdn$29 at Cantor Fitzgerald
-
Tilray (TLRY) PT Lowered to $11 at Cantor Fitzgerald
-
FINTECH ACQUISITION CORP. IV CLASS A COMMON SHARES AND WARRANTS TO COMMENCE TRADING SEPARATELY ON NOVEMBER 13, 2020
-
FINTECH ACQUISITION CORP. IV CLASS A COMMON SHARES AND WARRANTS TO COMMENCE TRADING SEPARATELY ON NOVEMBER 13, 2020
-
TherapeuticsMD (TXMD) Announces Underwritten Public Offering of its Common Stock
-
TherapeuticsMD Announces Underwritten Public Offering of its Common Stock
-
'The Most Significant Medical Breakthrough in 100 Years', 90% Effective Pfizer and BioNTech COVID-19 Vaccine Sends Stocks Surging
-
CF Finance Acquisition Corp. and GCM Grosvenor Announce Receipt of All Approvals Required for Business Combination
-
Celldex Therapeutics (CLDX) PT Raised to $22 at Cantor Fitzgerald
-
Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP
-
Cidara Provides Corporate Update and Reports Third Quarter 2020 Financial Results

